Continuing studies of carbonic anhydrase (CA) inhibitors, professors Raivis Žalubovskis’ (LIOS) and Claudiu T. Supuran’s groups showed that clinically used antibiotic Furagin and its derivatives possess inhibitory activity on human CA. It gives a solid base for the investigation of drug repurposing of Furagin for anti-cancer therapy. The research is published in the Journal of Enzyme Inhibition and Medicinal Chemistry (IF=4.027, 2018).
Read the article:
Pustenko, A., Nocentini, A., Gratteri, P., Bonardi, A., Vozny, I., Žalubovskis, R., Supuran, C.T.
The antibiotic furagin and its derivatives are isoform-selective human carbonic anhydrase inhibitors.
J. Enzyme Inhib. Med. Chem. 2020, 35 (1), p. 1011-1020, DOI: 10.1080/14756366.2020.1752201
